HUP0301671A3 - 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use - Google Patents

4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use

Info

Publication number
HUP0301671A3
HUP0301671A3 HU0301671A HUP0301671A HUP0301671A3 HU P0301671 A3 HUP0301671 A3 HU P0301671A3 HU 0301671 A HU0301671 A HU 0301671A HU P0301671 A HUP0301671 A HU P0301671A HU P0301671 A3 HUP0301671 A3 HU P0301671A3
Authority
HU
Hungary
Prior art keywords
neurokinin
phenyl
preparation
receptor antagonists
pyridine derivatives
Prior art date
Application number
HU0301671A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HUP0301671A2 publication Critical patent/HUP0301671A2/hu
Publication of HUP0301671A3 publication Critical patent/HUP0301671A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0301671A 2000-08-08 2001-07-27 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use HUP0301671A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117003 2000-08-08
PCT/EP2001/008686 WO2002016324A1 (en) 2000-08-08 2001-07-27 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0301671A2 HUP0301671A2 (hu) 2003-08-28
HUP0301671A3 true HUP0301671A3 (en) 2010-03-29

Family

ID=8169466

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301671A HUP0301671A3 (en) 2000-08-08 2001-07-27 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use

Country Status (36)

Country Link
US (1) US6770637B2 (en:Method)
EP (1) EP1309559B1 (en:Method)
JP (1) JP4053877B2 (en:Method)
KR (1) KR100518201B1 (en:Method)
CN (1) CN1293056C (en:Method)
AR (1) AR030324A1 (en:Method)
AT (1) ATE328871T1 (en:Method)
AU (2) AU1211802A (en:Method)
BR (1) BR0113173A (en:Method)
CA (1) CA2418868C (en:Method)
CZ (1) CZ2003684A3 (en:Method)
DE (1) DE60120419T2 (en:Method)
DK (1) DK1309559T3 (en:Method)
EC (1) ECSP034475A (en:Method)
ES (1) ES2264706T3 (en:Method)
GT (1) GT200100160A (en:Method)
HR (1) HRP20030055A2 (en:Method)
HU (1) HUP0301671A3 (en:Method)
IL (2) IL154079A0 (en:Method)
JO (1) JO2371B1 (en:Method)
MA (1) MA27680A1 (en:Method)
MX (1) MXPA03001143A (en:Method)
MY (1) MY128993A (en:Method)
NO (1) NO324841B1 (en:Method)
NZ (1) NZ523751A (en:Method)
PA (1) PA8524401A1 (en:Method)
PE (1) PE20020332A1 (en:Method)
PL (1) PL359849A1 (en:Method)
PT (1) PT1309559E (en:Method)
RU (1) RU2277087C2 (en:Method)
SI (1) SI1309559T1 (en:Method)
TW (1) TWI259180B (en:Method)
UY (1) UY26872A1 (en:Method)
WO (1) WO2002016324A1 (en:Method)
YU (1) YU8703A (en:Method)
ZA (1) ZA200300614B (en:Method)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
EP1763350B1 (en) * 2004-07-06 2011-12-21 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
BR0313255A (pt) 2002-08-08 2005-07-12 Amgen Inc Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto
EP1688408A3 (en) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
JP2007521276A (ja) * 2003-06-25 2007-08-02 スミスクライン・ビーチャム・コーポレイション Ｎｋ−２およびｎｋ−３として用いるための４−カルボキサミドキノリン誘導体
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
WO2005077938A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2006002860A1 (en) * 2004-07-06 2006-01-12 F. Hoffmann-La Roche Ag Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
MX2007012213A (es) * 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
MX2008002019A (es) * 2005-08-11 2008-04-16 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
EP1928886B1 (en) 2005-09-09 2011-04-13 GlaxoSmithKline LLC Pyridine derivatives and their use in the treatment of psychotic disorders
KR101561482B1 (ko) 2005-11-08 2015-10-20 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
HUE031913T2 (en) 2007-12-07 2017-08-28 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ585794A (en) 2007-12-07 2012-05-25 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA107088C2 (xx) * 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
FR2954315B1 (fr) * 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ME02446B (me) 2010-04-07 2016-09-20 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
WO2013049559A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CN108066306B (zh) 2012-01-25 2021-09-07 沃泰克斯药物股份有限公司 药物制剂及其制备方法
HK1209318A1 (en) 2012-07-16 2016-04-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP5806420B1 (ja) * 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
NZ720958A (en) 2013-11-12 2022-02-25 Vertex Pharma Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
HUE039062T2 (hu) 2014-04-15 2018-12-28 Vertex Pharma Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
US10538491B2 (en) * 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
EP3393519A1 (en) * 2015-12-22 2018-10-31 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors
US12473260B2 (en) * 2019-11-15 2025-11-18 KaNDy Therapeutics Limited Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56106286A (en) 1980-01-28 1981-08-24 Nippon Musical Instruments Mfg Electronic musical instrument
EP0103545A3 (en) 1982-09-13 1984-10-03 Arc Technologies Systems, Ltd. Electrode for arc furnaces
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
PL168236B1 (pl) * 1990-05-31 1996-01-31 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CN1067683C (zh) 1993-12-29 2001-06-27 默克·夏普-道姆公司 取代的吗啉衍生物及其作为治疗剂的用途
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE69628484T2 (de) * 1995-03-24 2004-05-19 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
WO1998021185A1 (en) * 1996-11-08 1998-05-22 Sankyo Company, Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
HUP0104933A3 (en) * 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
DK1035115T3 (da) * 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
IL144717A0 (en) * 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
EP1222800A2 (en) * 1999-10-14 2002-07-17 Telefonaktiebolaget LM Ericsson (publ) System and method of retrieving voice mail messages in a telecommunications network
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.

Also Published As

Publication number Publication date
AR030324A1 (es) 2003-08-20
KR20030022370A (ko) 2003-03-15
MY128993A (en) 2007-03-30
US20020040040A1 (en) 2002-04-04
AU2002212118B2 (en) 2005-12-15
IL154079A0 (en) 2003-07-31
MA27680A1 (fr) 2006-01-02
PT1309559E (pt) 2006-10-31
ES2264706T3 (es) 2007-01-16
YU8703A (sh) 2006-05-25
US6770637B2 (en) 2004-08-03
KR100518201B1 (ko) 2005-10-04
TWI259180B (en) 2006-08-01
AU1211802A (en) 2002-03-04
GT200100160A (es) 2002-05-16
IL154079A (en) 2008-03-20
HK1076459A1 (en) 2006-01-20
RU2277087C2 (ru) 2006-05-27
CZ2003684A3 (cs) 2003-11-12
PA8524401A1 (es) 2002-04-25
DE60120419D1 (de) 2006-07-20
UY26872A1 (es) 2002-01-31
CA2418868C (en) 2010-02-02
ECSP034475A (es) 2003-03-31
CN1293056C (zh) 2007-01-03
SI1309559T1 (sl) 2006-10-31
EP1309559A1 (en) 2003-05-14
JO2371B1 (en) 2006-12-12
CA2418868A1 (en) 2002-02-28
ATE328871T1 (de) 2006-06-15
NO20030632L (no) 2003-02-07
ZA200300614B (en) 2004-04-22
MXPA03001143A (es) 2003-06-24
NO324841B1 (no) 2007-12-17
NO20030632D0 (no) 2003-02-07
DK1309559T3 (da) 2006-10-02
HUP0301671A2 (hu) 2003-08-28
BR0113173A (pt) 2003-06-24
NZ523751A (en) 2004-08-27
PE20020332A1 (es) 2002-05-10
JP2004506718A (ja) 2004-03-04
CN1610670A (zh) 2005-04-27
JP4053877B2 (ja) 2008-02-27
DE60120419T2 (de) 2007-06-06
PL359849A1 (en) 2004-09-06
EP1309559B1 (en) 2006-06-07
HRP20030055A2 (en) 2005-02-28
WO2002016324A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
HUP0400570A3 (en) Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
AU6751301A (en) 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists
HUP0201033A3 (en) Glucagon antagonists/inverse agonists, process for their preparation and their use
IL153837A0 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU4667101A (en) Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
PL358584A1 (en) Cyclohexylamine derivative as subtype selective nmda receptor antagonists
HUP0303156A3 (en) Substituted 2-phenylaminoimidazoline derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
HUP0201571A2 (en) Il-8 receptor antagonist phenyl urea derivatives, process for the preparation thereof and pharmaceutical compositions containing them
AU2001261487A1 (en) Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
HUP0303045A3 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
AU8177801A (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
HUP0104804A3 (en) Tetrahydro-naphthyridinyl derivative as vitronectin receptor antagonist, process for its preparation and pharmaceutical composition containing the same
HUP0303513A3 (en) Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
HUP0300470A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
AU1025601A (en) Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
SI1268429T1 (en) Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same
AU2001293374A1 (en) Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal